Brokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) PT at $48.92

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have been assigned an average recommendation of “Buy” from the eighteen ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and four have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $50.1429.

Several brokerages recently issued reports on SRRK. BMO Capital Markets restated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Wolfe Research began coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Leerink Partners assumed coverage on Scholar Rock in a research report on Monday, September 15th. They issued an “outperform” rating and a $51.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th.

Scholar Rock Stock Performance

SRRK opened at $42.18 on Wednesday. Scholar Rock has a twelve month low of $22.71 and a twelve month high of $48.28. The firm has a market capitalization of $4.30 billion, a PE ratio of -13.39 and a beta of 0.63. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm’s 50-day moving average price is $40.70 and its 200 day moving average price is $36.60.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the firm earned ($0.66) EPS. As a group, sell-side analysts expect that Scholar Rock will post -2.42 EPS for the current fiscal year.

Insider Transactions at Scholar Rock

In other news, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.09, for a total value of $44,354.54. Following the completion of the transaction, the director owned 32,908 shares of the company’s stock, valued at approximately $1,450,913.72. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mo Qatanani sold 136,462 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the sale, the insider directly owned 108,964 shares in the company, valued at approximately $4,926,262.44. The trade was a 55.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

A number of large investors have recently made changes to their positions in SRRK. Wellington Management Group LLP lifted its stake in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the last quarter. Holocene Advisors LP purchased a new stake in shares of Scholar Rock during the 3rd quarter worth $91,670,000. Norges Bank purchased a new stake in shares of Scholar Rock during the 2nd quarter worth $41,628,000. Balyasny Asset Management L.P. acquired a new position in shares of Scholar Rock during the second quarter worth $33,062,000. Finally, UBS Group AG increased its holdings in Scholar Rock by 233.8% in the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock valued at $42,148,000 after buying an additional 792,760 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).